“The key to FDA’s public health mission, and its ability to bring innovative new therapies to patients, is the technical, scientific, and clinical expertise of its people,” wrote FDA Commissioner Gottlieb. “As the products that we’re asked to review become more complex and specialized, so do the technical demands on our workforce. Our staff must remain current with the dramatic advances in science and medicine and meet the increasing demands that globalization and other trends place on our core consumer protection functions.”
FDA Commissioner Gottlieb highlights that among the first jobs to be filled will be those to fulfil the agency’s commitments under its prescription drug user fee program. The House passed H.R. 2024, the FDA Reauthorization Act (FDARA) of 2017, which would reauthorize the program, last week.
Also referenced in the blog are provisions within the 21st Century Cures Act which grant the agency authority to hire skilled job candidates with unique experience at competitive salaries.
“All of these efforts will strengthen FDA’s core functions, enabling us to ensure that safe and effective advances can reach the patients who need them as efficiently as possible,” concluded FDA Commissioner Gottlieb.
Earlier this month, FDA Commissioner Gottlieb provided an update on the implementation of #CuresNow, and some of its key initiatives.
To view FDA’s implementation tracker of the 21st Century Cures Act, click HERE.